Literature DB >> 33437350

COVID-19 associated thromboinflammation of renal capillary: potential mechanisms and treatment.

Xiaojing Chen1,2, Chengyuan Yu3, Haijiao Jing2, Chunxu Wang2, Xinyi Zhao2, Jinming Zhang2, Shuoqi Zhang2, Huan Liu2, Rujuan Xie1, Jialan Shi2,4.   

Abstract

Coronavirus disease 2019 (COVID-19) infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic disease with high morbidity and mortality. Inflammatory and thrombosis are its main manifestations. As an important organ of hemofiltration metabolism, the kidney is prone to blockage and destruction when filter high inflammatory and high viscous blood of COVID-19, resulting in the loss of a large amount of protein, aggravating blood concentration, and then worsening COVID-19 hypercoagulability, which may explain the phenomenon of erythrocytes aggregation blocking the capillary lumen and the main reason why the kidney has become the second largest involvement organs. Therefore, this review discusses the effects of pathophysiological mechanisms such as inflammatory storm, endothelial injury, phosphatidylserine expression, extracellular traps release on renal capillary thrombosis caused by COVID-19 infection. Meanwhile, in view of the above mechanisms, we put forward the potential targets of antithrombotic therapy, and graded management of patients, reasonable use of drugs according to the severity of the disease and the choice of time. And we support the view of prevention of thrombus before admission, continuous anticoagulation and drug choice after discharge. It is suggested that the symptomatic and supportive treatment of renal disease in critically ill patients should be combined with the concept of antithrombotic therapy. The ultimate goal is to reduce the occurrence and development of kidney disease, provide direction for the current management of COVID-19 with kidney disease, and reduce the mortality of COVID-19. AJTR
Copyright © 2020.

Entities:  

Keywords:  COVID-19; antithrombotic therapy; graded management; inflammation; renal capillary thrombosis

Year:  2020        PMID: 33437350      PMCID: PMC7791506     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  103 in total

Review 1.  ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

Authors:  Andrew M South; Tammy M Brady; Joseph T Flynn
Journal:  Hypertension       Date:  2020-05-05       Impact factor: 10.190

Review 2.  Review: infectious diseases and coagulation disorders.

Authors:  E C van Gorp; C Suharti; H ten Cate; W M Dolmans; J W van der Meer; J W ten Cate; D P Brandjes
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

3.  Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients.

Authors:  Alpesh N Amin; Helen Varker; Nicole Princic; Jay Lin; Stephen Thompson; Stephen Johnston
Journal:  J Hosp Med       Date:  2011-12-21       Impact factor: 2.960

4.  Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation.

Authors:  Olivier P Blanc-Brude; Fabienne Archer; Patricia Leoni; Claudia Derian; Steven Bolsover; Geoffrey J Laurent; Rachel C Chambers
Journal:  Exp Cell Res       Date:  2004-12-01       Impact factor: 3.905

5.  Human IL-6, IL-17, IL-1β, and TNF-α differently regulate the expression of pro-inflammatory related genes, tissue factor, and swine leukocyte antigen class I in porcine aortic endothelial cells.

Authors:  Hanchao Gao; Lu Liu; Yanli Zhao; Hidetaka Hara; Pengfei Chen; Jia Xu; Jia Tang; Ling Wei; Zesong Li; David K C Cooper; Zhiming Cai; Lisha Mou
Journal:  Xenotransplantation       Date:  2017-03-17       Impact factor: 3.907

Review 6.  Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update.

Authors:  Hua Su; Chun-Tao Lei; Chun Zhang
Journal:  Front Immunol       Date:  2017-04-21       Impact factor: 7.561

7.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 8.  Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

Authors:  Behnood Bikdeli; Mahesh V Madhavan; Aakriti Gupta; David Jimenez; John R Burton; Caroline Der Nigoghossian; Taylor Chuich; Shayan Nabavi Nouri; Isaac Dreyfus; Elissa Driggin; Sanjum Sethi; Kartik Sehgal; Saurav Chatterjee; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Laurent Bertoletti; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Alfonso J Tafur; Dominic P Francese; Jaya Batra; Anna Falanga; Kevin J Clerkin; Nir Uriel; Ajay Kirtane; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; Martin B Leon; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2020-05-30       Impact factor: 5.249

Review 9.  Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Cristina Belizna; Albert Selva-O'Callaghan; Josep Pardos-Gea; Angela Quintana; Arsene Mekinian; Ariadna Anunciacion-Llunell; Francesc Miró-Mur
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

Review 10.  Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms.

Authors:  Federica Raucci; Adel Abo Mansour; Gian Marco Casillo; Anella Saviano; Francesco Caso; Raffaele Scarpa; Nicola Mascolo; Asif Jilani Iqbal; Francesco Maione
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

View more
  5 in total

Review 1.  Neutrophil Extracellular Traps (NETs) in Severe SARS-CoV-2 Lung Disease.

Authors:  Monika Szturmowicz; Urszula Demkow
Journal:  Int J Mol Sci       Date:  2021-08-17       Impact factor: 5.923

Review 2.  Mechanisms of COVID-19 thrombosis in an inflammatory environment and new anticoagulant targets.

Authors:  Huan Liu; Tianshui Hu; Cong Zhang; Xiaojing Chen; Shuoqi Zhang; Mengdi Li; Haijiao Jing; Chunxu Wang; Tenglong Hu; Jialan Shi
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 3.  The Central Role of Extracellular Vesicles in the Mechanisms of Thrombosis in COVID-19 Patients With Cancer and Therapeutic Strategies.

Authors:  Haijiao Jing; Nan Zuo; Valerie A Novakovic; Jialan Shi
Journal:  Front Cell Dev Biol       Date:  2022-01-12

Review 4.  The Emerging Role of Neutrophils in the Pathogenesis of Thrombosis in COVID-19.

Authors:  Valeria Iliadi; Ina Konstantinidou; Konstantina Aftzoglou; Sergios Iliadis; Theocharis G Konstantinidis; Christina Tsigalou
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 5.  Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury.

Authors:  Chengyue Wang; Chengyuan Yu; Valerie A Novakovic; Rujuan Xie; Jialan Shi
Journal:  Front Cell Dev Biol       Date:  2022-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.